Valproic acid capsule delayed release dosage forms and strengths

Jump to navigation Jump to search
Valproic acid
DEPAKENE® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
STAVZOR® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Valproic acid
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Dosage Forms & Strengths

  • 125-mg orange-colored, oval-shaped capsules with NVN in black print
  • 250-mg orange-colored, oval-shaped capsules with NVN1 in black print
  • 500-mg orange-colored, oval-shaped capsules with NVN2 in black print[1]

References

  1. "STAVZOR (VALPROIC ACID) CAPSULE, DELAYED RELEASE STAVZOR ( VALPROIC ACID) CAPSULE, DELAYED RELEASE [NOVEN THERAPEUTICS, LLC]".

Adapted from the FDA Package Insert.